Smart Assays Biotechnologies
| ISIN | 🆔 |
|---|---|
| Industry | |
| Founded 📆 | 2005 |
| Founder 👔 | |
| Headquarters 🏙️ | Weizmann Science Park, Ness Ziona,ISRAEL |
Area served 🗺️ | |
Key people | |
| Services |
|
| Members | |
Number of employees | |
| 🌐 Website | http://www.asssays.co.il |
| 📇 Address | |
| 📞 telephone | |
Mission[edit]
Smart Assays Biotechnologies is an Israeli-based contract research organization (CRO) founded in 2005 by Dr. Raphael Mayer, Ph.D. The company provides tailor-made R&D services for biotechnology, food and pharmaceutical companies. Smart Assays Biotechnologies is the first of its kind to provide a solution to the issue of replication crisis by conducting replication studies that qualify academic research to mature to industry-level R&D [2]. The company's original risk management model for investment in early-stage biomed companies was presented at the international 'Israel Biomed 2013' conference in June 2013 [3]. Specific experience ranges from work plan design, through assay development process, establishment of validated assays and up to the final stage of technology transfer to the customer’s facility.
As one of the biggest concerns for potential investors and entrepreneurs is low repeatability of academic research [4][5](also known as the replication crisis), Smart Assays’ activities focus on verification and validation of biotechnological methods, active compounds and drugs with market potential. For example, Smart Assays conducted a replication study that demonstrated the activity of the anti-HIV drug Gammora [6].
As of 2019, The company employs a staff of eleven people, eight of which hold a Ph.D. degree in Biology, Biochemistry or Chemistry [7].
Research projects and activities[edit]
The scope of Smart Assays Biotechnologies’ activity includes research histopathology, bioanalytical research, biochemical research and deciphering complex biochemical mechanisms. The company operates under ISO 9001:2015 certification [8].
- In February 2014, Can-Fite BioPharma announced that it is collaborating with Smart Assays to develop a commercial biomarker blood test kit for A3 adenosine receptor (ASAR) status, which is intended for screening suitable candidates for treatment with the drug CF101 [9][10][11].
- In 2017, Smart Assays Biotechnologies announced a collaboration with Aptuit, which supported the customer in development of new histopathological models in animals [12]
- In 2017, Smart Assays Biotechnoliogies conuctded a project with the Canadian company Replicor [13]. As part of this project, a fluorescence-polarization assay was developed and validated for the cell-free examination of protein interactions with nucleic acid polymers.
- In 2018, Smart Assays conducted a mode-of-action elucidation study for Biosight BST-236, a Novel Cytarabine Prodrug, in in-vivo Leukemia models [14].
- Smart Assays Biotechnoliogies participates in the EU OLEUM project, by developing practical methods for olive oil analyses by means of fluorescence techniques to detect chlorophyll, tocopherols, and phenolics to test olive oil freshness and predict its quality[15][16].
References[edit]
- ↑ "היום יותר מתמיד, קשה לפתח תרופה בלי להבין את מנגנון הפעולה שלה - December 13 2018- Globes [online], Israel Business News". www.globes.co.il. Retrieved 18 November 2019.
- ↑ "Company- Smart Assays". assays.co.il. Retrieved 16 November 2019.
- ↑ "סמארט אסייס תחשוף בשבוע ביומד ישראל 2013". Retrieved 18 November 2019.
- ↑ Prinz, Florian (2011-08-31). "Believe it or not: how much can we rely on published data on potential drug targets". Nature Reviews Drug Discovery. 10 (712): 712. doi:10.1038/nrd3439-c1. PMID 21892149.
- ↑ Baker, Monia (2016-05-25). "1,500 scientists lift the lid on reproducibility". Nature. 533 (7604): 452–454. Bibcode:2016Natur.533..452B. doi:10.1038/533452a.
- ↑ "JB holdings Pharmaceutical key achievements". www.jb-holdings.co.za. Retrieved 16 November 2019.
- ↑ "About- Smart Assays". assays.co.il. Retrieved 16 November 2019.
- ↑ "ISO 9001:2015 certificate" (PDF). Retrieved 16 November 2019.
- ↑ "Can-Fite BioPharma awaiting future catalysts- July 2014". Edison Group Investment Research.
- ↑ "Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit - April 21 2014". www.news-medical.net. Retrieved 16 November 2019.
- ↑ "Smart Assays כן פייט ביופרמה חתמה על הסכם שיתוף פעולה עם - April 22 2014". www.bizportal.co.il. Retrieved 18 November 2019.
- ↑ "Medical research services co Smart Assays will help Aptuit in Israel, and Aptuit will help the Israeli company overseas.- September 24 2017 19:32 - Globes [online], Israel Business News". wwww.globes.co.il. Retrieved 18 November 2019.
- ↑ "interaction of nucleic acid polymers with the large and small forms of the hepatitis delta antigen protein" (PDF). Replicor WP content.
- ↑ Tessler, Shoshi; Mishalian, Inbal; Peri-Naor, Ronny; Gengrinovitch, Stela; Mayer, Raphael; Ben Yakar, Ruth; Peled, Amnon; Flaishon, Liat (2018-11-29). "BST-236, a Novel Cytarabine Prodrug, Is Safer and As Effective As Cytarabine in In Vivo Leukemia Models". Blood. 132 (Supplement 1): 1454. doi:10.1182/blood-2018-99-112092.
- ↑ "Get to know Smart Assays". OLEUM @OLEUM_EU.
- ↑ "Partners Smart Assays". www.oleumproject.eu.
This article "Smart Assays Biotechnologies" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Smart Assays Biotechnologies. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
